Long‐Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy‐Six–Week Phase III Parent Study in the United States

OBJECTIVE: We undertook this US multicenter continuation study (GlaxoSmithKline study BEL112233; ClinicalTrials.gov identifier: NCT00724867) to assess long‐term safety and efficacy of belimumab in patients with systemic lupus erythematosus (SLE) who completed the Study of Belimumab in Subjects with...

Descripción completa

Detalles Bibliográficos
Autores principales: Furie, Richard A., Wallace, Daniel J., Aranow, Cynthia, Fettiplace, James, Wilson, Barbara, Mistry, Prafull, Roth, David A., Gordon, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001779/
https://www.ncbi.nlm.nih.gov/pubmed/29409143
http://dx.doi.org/10.1002/art.40439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001779/
https://www.ncbi.nlm.nih.gov/pubmed/29409143
http://dx.doi.org/10.1002/art.40439

Ejemplares similares